⚔️ Head-to-head

Ipamorelin vs Sermorelin

Pep lines up the two side by side — verdict, mechanism, and the dimensions that actually differ — so you can see where each one wins.

By MrPepTalks Editorial · Updated 2026-07-08

Ipamorelin vs Sermorelin

Ipamorelin

NNC 26-0161

unproven

Sermorelin

Sermorelin acetate · GRF 1-29 · Geref

unproven

🏆 Wins on evidence grade / stage

Ipamorelin
Dimension
Sermorelin
Ghrelin-mimetic growth-hormone secretagogue (a GHS-receptor agonist pentapeptide).
Peptide class
GHRH analog — a 29-amino-acid fragment of growth-hormone-releasing hormone (GRF 1-29).
Acts on the ghrelin / GH-secretagogue receptor to prompt a growth-hormone pulse; marketed as selective, with less reported effect on cortisol or prolactin than older GHRPs.
How it signals
Copies the body's own upstream GHRH signal, asking the pituitary to release its own growth hormone rather than replacing the downstream hormone.
Commonly researched for growth-hormone release and recovery; the physique and age-related uses people search for are not what controlled human trials measured.
Commonly researched for
Historically studied as a diagnostic agent for pituitary growth-hormone reserve and for childhood growth-hormone deficiency; the adult age-reversal and body-composition uses are off-label.
Evidence tier C: the human file is largely mechanism and marker data, with no large controlled trials on the outcomes it is marketed for.
Evidence grade / stage
Evidence tier B: older human pharmacology and diagnostic use, plus pediatric growth-deficiency studies — more human history, but none measuring adult physique outcomes.
🏆 winner
Studies reported measurable rises in growth-hormone and IGF-1 markers; no large trial reported documented changes in how adults look, sleep, or perform.
What the trials reported
Studies reported rises in growth-hormone and IGF-1 markers and usable pituitary-response readings in diagnostic use; adult look-and-feel outcomes were not the measured endpoint.
Reported effects include injection-site reactions (redness, pain, swelling), headache, flushing, and dizziness; gray-market sourcing adds contamination and mislabeling risk.
Reported side-effect profile
Reported effects include injection-site reactions, flushing, headache, dizziness, nausea, and altered taste; the same unregulated-sourcing risks apply.
Not FDA-approved; sold as a research chemical for laboratory use only, and it has never had an approved prescription product.
Regulatory status
Not currently FDA-approved; the former prescription product Geref was discontinued from the US market, and it is now sold mainly via compounding pharmacies or as a research chemical.
On the WADA prohibited list, so a tested athlete can fail a drug test.
Anti-doping status
On the WADA prohibited list, so a tested athlete can fail a drug test.
Available only as a research chemical from gray-market suppliers, with no pharmacy-grade product and unverified quality.
Availability
Available mainly through compounding pharmacies or as a research chemical; no current standard FDA-approved product on the US market.
Different receptor, different job: as a ghrelin-mimetic it is often studied alongside a GHRH analog rather than instead of one, which is why the two are frequently paired in research discussion.
Head-to-head takeaway
The GHRH half of that pairing, with more human and diagnostic history behind it; neither peptide has large human outcome data for the adult goals both are marketed toward, so both verdicts stay Unproven.
Ipamorelin data sheetThe terse reference: facts, forms, and Pep's verdict.Sermorelin data sheetThe terse reference: facts, forms, and Pep's verdict.
Send it to me →

No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.